NUWE Nuwellis Inc

$NUWE this sh*t was made to steal your money. And still doing the same. Should have been investigated and kicked out from Nasdaq long time ago! Rot in hell nuwellis!🖕🖕

$NUWE Good Lord I noticed the low of the day was 0.44 . No position here and avoiding someof the penny stocks that are getting decimated. VCIG , GMM, VJET, RUBI ,......... and so on have been destroyed.

$NUWE Hibernation mode. Basically it has been consolidating around 0.70 until the next pump and dump.

$NUWE It has been consolidating for awhile around 0.70s given or taken. The upside at this price is far greater than the downside making it a good opportunity with not so much risk . Expect this to get pumped some time soon.

$NUWE Watching for a position. Damn. Can this trade sideways for once for couple days. Watching scale in. Checking in. Last time looked at float was around 500k Think was lower. Now showing 3.6 million shares in float. Thought they had cash runway into 3q 2027. Keep eyes here eod. You know how it works on small caps. Buy when no-one wants it. No position yet. Am watching.

$NUWE NUWE is listed by Stocktwits as DOWN 100% in 5 years.....So why hasn't the SEC removed it's shares?

$NUWE memory recall when mo the grid player promised 130 and 400 per share. What a clown

$NUWE Dilution Friday again?.....Would anyone pay $100 for this Money Losing Penny Stock?.....Will it be delisted?

$NUWE — Nuwellis's recent analyses covered a divergence between strong revenue growth and a deeply bearish technical trend, alongside strategic product expansion. Recent analyses for NUWE examined a significant disconnect between positive revenue growth and strategic developments, and a strongly bearish technical price trend. The company reported double-digit revenue growth and expanded its critical care portfolio, while market indicators showed substantial price declines and weakness below key moving averages. Supportive points: Year-over-year quarterly revenue growth of 14.1% reported. Revenue growth supported by an increase in the installed base. Commercial agreement with Atrility Medical for critical care portfolio expansion. Concerns raised: Price significantly below 50-day and 200-day SMAs. Price down substantially over the last 7, 30, and 91 days. 10-day EMA below 50-day SMA indicating short-term weakness. RSI in oversold territory (30.13 in one analysis).